The role of glucagon in the pathogenesis of the endogenous hyperglycemia of diabetes mellitus
Abstract
The effect of glucagon suppression by somatostatin upon endogenous hyperglycemia was studied in three forms of experimental insulin deficiency in dogs: alloxan diabetes, total pancreatectomy, and diazoxide administration. In six insulin-requiring alloxan-diabetic dogs deprived of insulin for 24 hr, mean plasma glucose declined to 77% +/- 6% of the baseline level of 350 +/- 41 mg/dl during 3 hr of glucagon suppression, significantly below the unsuppressed saline controls (p less than 0.01-0.05). When somatostatin was discontinued, glucagon rose and glucose increased 21% (p less than 0.05) in 30 min. Significant correlation between maximal changes in glucagon and glucose was observed (r = 0.81; p less than 0.001). Even during a 1-hr alanine infusion in such dogs, glucose declined an average of 36 +/- 9 mg/dl, instead of rising 51 +/- 7 mg/dl as in unsuppressed controls. Maximal changes in glucagon and glucose were correlated (r = 0.85; p less than 0.01). In eight depancreatized dogs pretreated intravenously with continuous insulin and glucose infusions, withdrawal of insulin was followed by a rise in extrapancreatic glucagon; mean plasma glucose rose from 212 +/- 43 to 415 +/- 80 mg/dl 270 min after the end of the insulin infusion. However, when glucagon was suppressed after insulin withdrawal, glucose remained below 240 mg/dl, significantly less than the controls (p less than 0.005); when somatostatin was stopped, glucagon rose and glucose increased 88 +/- 19 mg/dl within an hour. The rises in glucagon and glucose were significantly correlated (r = 0.68; p less than 0.05). Glucagon suppression by somatostatin during diazoxide-induced blockade of insulin secretion in four normal dogs reduced hyperglycemia significantly but did not prevent it. The results support the hypothesis that a relative or absolute excess of glucagon, as well as a relative or absolute deficiency of insulin, is etiologically important in the development of endogenous hyperglycemia in diabetes mellitus, the hyperglucagonemia probably mediating the glucose overproduction.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The multi-receptor agonism approach to weight loss was hindered by commercial considerations of production and formulation, the biological impasse that glucagon potently induces hyperglycemia, and potential dose-limiting cardiovascular liabilities.
“However, this multi-receptor agonism approach to weight loss was hindered by commercial considerations of production and formulation [45], the biological impasse that glucagon potently induces hyperglycemia [56,57], and potential dose-limiting cardiovascular liabilities arising from positive chronotropic actions to influence hemodynamic parameters [58].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [57]
Cites
Glucagon: Role in the Hyperglycemia of Diabetes Mellitus
Dobbs, R., Sakurai, H., Sasaki, H., Faloona, G., Valverde, I., Baetens, D., Orci, L., & Unger, R. (1975) · Science · doi:10.1126/science.1089999 · Cited by 229 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Cherrington, A. D., Chiasson, J. L., Liljenquist, J. E., Jennings, A. S., Keller, U., & Lacy, W. W. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108596 · Cited by 249 · see citing works
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 147 · see citing works
Robson-Doucette, C. A., Sultan, S., Allister, E. M., Wikstrom, J. D., Koshkin, V., Bhattacharjee, A., Prentice, K. J., Sereda, S. B., Shirihai, O. S., & Wheeler, M. B. (2011) · Diabetes · doi:10.2337/db11-0132 · Cited by 136 · see citing works
Retatrutide: A Triple Incretin Receptor Agonist for Obesity Management
Ray, A. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2276754 · Cited by 11 · see citing works
- Authors
- Sakurai, H., Dobbs, R. E., & Unger, R. H.
- Affiliations
- United States Department of Veterans Affairs (US)
- Corresponding author
- Unger, Roger H.
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 1975-11
- Volume
- 24
- Issue
- 11
- Pages
- 1287-1297
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W2073158702
- Cited by
- 62
- References
- 1
- Citations by year
- 2023: 2 · 2022: 2 · 2021: 2 · 2018: 1
- FWCI
- 18.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, somatostatin, hyperglycemia, diabetes pathogenesis, alloxan-induced diabetes, total pancreatectomy, diazoxide, insulin deficiency, hyperglucagonemia, alanine infusion, dogs, insulin withdrawal, plasma glucose regulation, glucose counterregulation
- MeSH terms
- Animals, Blood Glucose, Diabetes Mellitus, Experimental, Diazoxide, Dogs, Glucagon, Hyperglycemia, Pancreas, Pancreatectomy, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review